A useful cell system for studying the regulation of 17HSD/KSR type 2 activity and expression in ovarian epithelial cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 122, Issue 4, 2010, Pages 295-301

  Provost, Pierre R ^a   Lima, Paul H ^b   Tremblay, Yves ^a   Blomquist, Charles H ^b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

17 Hydroxysteroid dehydrogenase type 1; 17 Hydroxysteroid dehydrogenase type 2; 17 Hydroxysteroid dehydrogenase type 4; 17 Hydroxysteroid dehydrogenase type 5; Ovarian cancer cells

Indexed keywords

17 HYDROXYSTEROID DEHYDROGENASE; ANDROSTERONE; MESSENGER RNA; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 1; TESTOSTERONE 17BETA DEHYDROGENASE 2; TESTOSTERONE 17BETA DEHYDROGENASE 4; TESTOSTERONE 17BETA DEHYDROGENASE 5; UNCLASSIFIED DRUG; 3 (OR 17)-BETA-HYDROXYSTEROID DEHYDROGENASE; HYDROXYSTEROID DEHYDROGENASE;

ARTICLE; CANCER CELL CULTURE; CULTURE MEDIUM; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION; ADENOCARCINOMA; ENZYMOLOGY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

BOVINAE;

17-HYDROXYSTEROID DEHYDROGENASES; ADENOCARCINOMA; BLOTTING, WESTERN; CELL LINE, TUMOR; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; RNA, MESSENGER;

EID: 77957271811     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.06.008     Document Type: Article

References (54)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA: Cancer J. Clin. 2008, 58:71-96.
2. Rao G.G., Miller D.S. Hormonal therapy in epithelial ovarian cancer. Expert Rev. Anticancer Ther. 2006, 6:43-47.
3. Salehi F., Dunfield L., Phillips K.P., Krewski D., Vanderhyden B.C. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J. Toxicol. Environ. Health 2008, 11:301-321.
4. Walker G., MacLeod K., Williams A.R., Cameron D.A., Smyth J.F., Langdon S.P. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol. Oncol. 2007, 106:461-468.
5. Penning T.M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr. Rev. 1997, 18:281-305.
6. Meier M., Moller G., Adamski J. Perspectives in understanding the role of human 17beta-hydroxysteroid dehydrogenases in health and disease. Ann. N.Y. Acad. Sci. 2009, 1155:15-24.
7. Prehn C., Moller G., Adamski J. Recent advances in 17beta-hydroxysteroid dehydrogenases. J. Steroid Biochem. Mol. Biol. 2009, 114:72-77.
8. Mindnich R., Möller G., Adamski J. The role of 17 beta-hydroxysteropid dehydrogenases. Mol. Cell. Endocrinol. 2004, 218:7-20.
9. Gershenson D.M., Tortolero-Luna G., Malpica A., Baker V.V., Whittaker L., Johnson E., Follen Mitchell M. Ovarian intraepithelial neoplasia and ovarian cancer. Obstet. Gynecol. Clin. North Am. 1996, 23:475-543.
10. Scully R.E. Pathology of ovarian cancer precursors. J. Cell. Biochem. 1995, 23:208-218.
11. Clinton G.M., Hua W. Estrogen action in human ovarian cancer. Crit. Rev. Oncol. Hematol. 1997, 25:1-9.
12. Rao B.R., Slotman B.J. Endocrine factors in common epithelial ovarian cancer. Endocr. Rev. 1991, 12:14-26.
13. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J. Natl. Cancer Inst. 1998, 90:1774-1786.
14. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 2001, 22:255-288.
15. Rae M.T., Niven D., Ross A., Forster T., Lathe R., Critchley H.O., Ghazal P., Hillier S.G. Steroid signalling in human ovarian surface epithelial cells: the response to interleukin-1alpha determined by microarray analysis. J. Endocrinol. 2004, 183:19-28.
16. Heinonen P.K., Koivula T., Rajaniemi H., Pystynen P. Peripheral and ovarian venous concentrations of steroid and gonadotropin hormones in postmenopausal women with epithelial ovarian tumors. Gynecol. Oncol. 1986, 25:1-10.
17. Rae M.T., Hillier S.G. Steroid signalling in the ovarian surface epithelium. Trends Endocrinol. Metab. 2005, 16:327-333.
18. Blomquist C.H., Leung B.S., Zhang R.P., Zhu Y.Y., Chang P.M. Properties and regulation of 17 beta-hydroxysteroid oxidoreductase of OVCAR-3, CAOV-3, and A431 cells: effects of epidermal growth factor, estradiol, and progesterone. J. Cell. Biochem. 1995, 59:409-417.
19. Blomquist C.H., Bonenfant M., McGinley D.M., Posalaky Z., Lakatua D.J., Tuli-Puri S., Bealka D.G., Tremblay Y. Androgenic and estrogenic 17beta-hydroxysteroid dehydrogenase/17-ketosteroid reductase in human ovarian epithelial tumors: evidence for the type 1, 2 and 5 isoforms. J. Steroid Biochem. Mol. Biol. 2002, 81:343-351.
20. Chura J.C., Ryu H.S., Simard M., Poirier D., Tremblay Y., Brooker D.C., Blomquist C.H., Argenta P.A. Steroid-converting enzymes in human ovarian carcinomas. Mol. Cell. Endocrinol. 2009, 301:51-58.
21. Provencher D.M., Lounis H., Champoux L., Tetrault M., Manderson E.N., Wang J.C., Eydoux P., Savoie R., Tonin P.N., Mes-Masson A.M. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell. Dev. Biol. 2000, 36:357-361.
22. Lounis H., Provencher D., Godbout C., Fink D., Milot M.J., Mes-Masson A.M. Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp. Cell Res. 1994, 215:303-309.
23. Blomquist C.H. Kinetic analysis of enzymic activities: prediction of multiple forms of 17 beta-hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol. 1995, 55:515-524.
24. Provost P.R., Blomquist C.H., Godin C., Huang X.-F., Flamand N., Luu-The V., Nadeau D., Tremblay Y. Androgen formation and metabolism in the pulmonary epithelial cell line A-549: expression of 17β-hydroxysteroid dehydrogenase type 5 and 3α-hydroxysteroid dehydrogenase type 3. Endocrinology 2000, 141:2786-2794.
25. Tremblay Y., Tretjakoff I., Peterson A., Antakly T., Zhang C.X., Drouin J. Pituitary-specific expression and glucocorticoid regulation of a proopiomelanocortin fusion gene in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:8890-8894.
26. Tremblay Y., Ringler G.E., Morel Y., Mohandas T.K., Labrie F., Strauss J.F., Miller W.L. Regulation of the gene for estrogenic 17-ketosteroid reductase lying on chromosome 17cen→Q25. J. Biol. Chem. 1989, 264:20458-20462.
27. Beaudoin C., Blomquist C.H., Tremblay Y. Gene expression of 17β-hydroxysteroid dehydrogenase type 2 isozyme in primary cultures of human trophoblasts predicts different mechanisms regulating type 1 and type 2 enzymes. Endocrinology 1995, 136:3807-3814.
28. Provost P., Tremblay Y. Length increase of the human alpha-globin 3′-untranslated region disrupts stability of the pre-mRNA but not that of the mature mRNA. J. Biol. Chem. 2000, 275:30248-30255.
29. Adamski J., Normand T., Leenders F., Monté D., Begue A., Stéhelin D., Jungblut P.W., de Launoit Y. Molecular cloning of a novel widely expressed human 80kDa 17β-hydroxysteroid dehydrogenase IV. Biochem. J. 1995, 311:437-443.
30. Feinberg A.P., Vogelstein B. A technique for radiolabelling DNA restriction endonuclease fragments. Anal. Biochem. 1983, 132:6-13.
31. Provost P.R., Simard M., Tremblay Y. A link between lung androgen metabolism and the emergence of mature epithelial type II cells. Am. J. Respir. Crit. Care Med. 2004, 170:296-305.
32. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3. RESEARCH0034.
33. Drolet R., Simard M., Plante J., Laberge P., Tremblay Y. Human type 2 17beta-hydroxysteroid dehydrogenase mRNA and protein distribution in placental villi at mid and term pregnancy. Reprod. Biol. Endocrinol. 2007, 5:30.
34. Lin H.-K., Steckelbroeck S., Fung K.-M., Jones A.N., Penning T.H. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha HSD/type 5 17betaHSD); immunohistochemical detection in breast and prostate. Steroids 2004, 69:795-801.
35. Wu L., Einstein M., Geissler W.M., Chan H.K., Elliston O., Andersson S. Expression cloning and characterization of human 17β-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20α-hydroxysteroid dehydrogenase activity. J. Biol. Chem. 1993, 268:12964-12969.
36. Provost P.R., Blomquist C.H., Drolet R., Flamand N., Tremblay Y. Androgen inactivation in human lung fibroblasts: variations in levels of 17β-hydroxysteroid dehydrogenase type 2 and 5α-reductase activity compatible with androgen inactivation. J. Clin. Endocrinol. Metab. 2002, 87:3883-3892.
37. Blomquist C.H., Leung B.S., Beaudoin C., Poirier D., Tremblay Y. Kinetic behavior in vitro and the dehydrogenase/reductase activity ratio of A431 cells in culture suggest intracellular regulation of 17b-hydroxysteroid dehydrogenase type 2 at the level of catalysis to function predominantly as a dehydrogenase. J. Endocrinol. 1997, 153:453-464.
38. Husen B., Psonka N., Jacob-Meisel M., Keil C., Rune G.M. Differential expression of 17beta-hydroxysteroid dehydrogenases types 2 and 4 in human endometrial epithelial cell lines. J. Mol. Endocrinol. 2000, 24:135-144.
39. L'Esperance S., Bachvarova M., Tetu B., Mes-Masson A.M., Bachvarov D. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 2008, 9:99.
40. Gagné J.P., Gagné P., Hunter J.M., Bonicalzi M.E., Lemay J.F., Kelly I., Le Page C., Provencher D., Mes-Masson A.M., Droit A., Bourgais D., Poirier G.G. Proteome profiling of human epithelial ovarian cancer cell line TOV-112D. Mol. Cell. Biochem. 2005, 275:25-55.
41. Vierikko P., Kauppila A., Vihko R. Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumors of the human ovary. Int. J. Cancer 1983, 32:413-422.
42. Sasano H., Suzuki T., Niikura H., Kaga K., Sato S., Yajima A., Rainey W.E., Nagura H. 17 beta-hydroxysteroid dehydrogenase in common epithelial ovarian tumors. Mod. Pathol. 1996, 9:386-391.
43. Gunnarsson C., Olsson B.M., Stal O. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res. 2001, 61:8448-8451.
44. Day J.M., Tutill H.J., Newman S.P., Purohit A., Lawrence H.R., Vicker N., Potter B.V., Reed M.J. 17Beta-hydroxysteroid dehydrogenase Type 1 And Type 2: association between mRNA expression and activity in cell lines. Mol. Cell. Endocrinol. 2006, 248:246-249.
45. Castagnetta L.A., Carruba G., Traina A., Granata O.M., Markus M., Pavone-Macaluso M., Blomquist C.H., Adamski J. Expression of different 17beta-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells. Endocrinology 1997, 138:4876-4882.
46. Jansson A., Gunnarsson C., Stal O. Proliferative responses to altered 17beta-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors. Endocr. Relat. Cancer 2006, 13:875-884.
47. Fiorelli G., Picariello L., Martineti V., Tognarini I., Tonelli F., Brandi M.L. Estrogen metabolism in human colorectal cancer cells. J. Steroid Biochem. Mol. Biol. 2002, 81:281-289.
48. Cheng Y.H., Imir A., Fenkci V., Yilmaz M.B., Bulun S.E. Stromal cells of endometriosis fail to produce paracrine factors that induce epithelial 17beta-hydroxysteroid dehydrogenase type 2 gene and its transcriptional regulator Sp1: a mechanism for defective estradiol metabolism. Am. J. Obstet. Gynecol. 2007, 196:391. e391-397; discussion 391, e397-398.
49. Cheng Y.H., Yin P., Xue Q., Yilmaz B., Dawson M.I., Bulun S.E. Retinoic acid (RA) regulates 17beta-hydroxysteroid dehydrogenase type 2 expression in endometrium: interaction of RA receptors with specificity protein (SP) 1/SP3 for estradiol metabolism. J. Clin. Endocrinol. Metab. 2008, 93:1915-1923.
50. Khan N., Sharma K.K., Andersson S., Auchus R.J. Human 17beta-hydroxysteroid dehydrogenases types 1, 2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells. Arch. Biochem. Biophys. 2004, 429:50-59.
51. Lee P., Rosen D.G., Zhu C., Silva E.G., Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol. Oncol. 2005, 96:671-677.
52. Oduwole O.O., Makinen M.J., Isomaa V.V., Pulkka A., Jernvall P., Karttunen T.J., Vihko P.T. 17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer. J. Steroid Biochem. Mol. Biol. 2003, 87:133-140.
53. Blomquist C.H., Lima P.H., Hotchkiss J.R. Inhibition of 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD) activity of human lung microsomes by genistein, daidzein, coumestrol and C(18)-, C(19)- and C(21)-hydroxysteroids and ketosteroids. Steroids 2005, 70:507-514.
54. Moller G., Deluca D., Gege C., Rosinus A., Kowalik D., Peters O., Droescher P., Elger W., Adamski J., Hillisch A. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone. Bioorg. Med. Chem. Lett. 2009, 19:6740-6744.